H

Hana Pharm Co Ltd
KRX:293480

Watchlist Manager
Hana Pharm Co Ltd
KRX:293480
Watchlist
Price: 11 690 KRW 0.6% Market Closed
Market Cap: 207.7B KRW

Relative Value

The Relative Value of one Hana Pharm Co Ltd stock under the Base Case scenario is 21 021.54 KRW. Compared to the current market price of 11 690 KRW, Hana Pharm Co Ltd is Undervalued by 44%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
21 021.54 KRW
Undervaluation 44%
Relative Value
Price
H
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
85
vs Industry
74
Median 3Y
1
Median 5Y
1.2
Industry
2.6
Forward
0.8
vs History
71
vs Industry
40
Median 3Y
10.2
Median 5Y
10.6
Industry
21.7
Forward
15.4
vs History
82
vs Industry
43
Median 3Y
8.8
Median 5Y
10.4
Industry
16.6
vs History
20
vs Industry
26
Median 3Y
21
Median 5Y
14.2
Industry
22.5
vs History
90
vs Industry
70
Median 3Y
0.8
Median 5Y
0.9
Industry
2.3
vs History
87
vs Industry
73
Median 3Y
1.1
Median 5Y
1.2
Industry
2.9
Forward
0.9
vs History
87
vs Industry
77
Median 3Y
1.7
Median 5Y
1.9
Industry
5.5
vs History
84
vs Industry
43
Median 3Y
6.6
Median 5Y
6.9
Industry
13.1
Forward
5.5
vs History
49
vs Industry
41
Median 3Y
8.6
Median 5Y
8.6
Industry
16.6
Forward
7.2
vs History
85
vs Industry
43
Median 3Y
9.2
Median 5Y
10.1
Industry
15.8
vs History
25
vs Industry
25
Median 3Y
27.5
Median 5Y
19.5
Industry
19.1
vs History
90
vs Industry
71
Median 3Y
0.7
Median 5Y
0.8
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Hana Pharm Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Hana Pharm Co Ltd
KRX:293480
202.2B KRW 0.9 10.2 6.4 8.6
US
Eli Lilly and Co
NYSE:LLY
952.1B USD 16.1 51.9 34.8 37.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
494.4B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
253.5B CHF 4.1 26.9 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 4.9 30.1 108.3 158.5
CH
Novartis AG
SIX:NOVN
205.7B CHF 4.6 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
245.7B USD 3.8 12.9 9.2 10.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.7 8.9 10.3
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
146.6B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
KR
H
Hana Pharm Co Ltd
KRX:293480
Average P/E: 21.9
10.2
14%
0.7
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.9
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.1
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
12.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
H
Hana Pharm Co Ltd
KRX:293480
Average EV/EBITDA: 398.3
6.4
12%
0.5
US
Eli Lilly and Co
NYSE:LLY
34.8
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
2%
4.4
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
H
Hana Pharm Co Ltd
KRX:293480
Average EV/EBIT: 1 708.4
8.6
14%
0.6
US
Eli Lilly and Co
NYSE:LLY
37.2
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.9
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3